
Blog
Using synthetic gene circuits to better control the timing of immunotherapy
CAR T cell therapies are generally optimized for short-term cellular
CAR T cell therapies are generally optimized for short-term cellular
Researchers have bolstered the power of chimeric antigen receptor (CAR)-T
Researchers have created a laboratory-developed, three-dimensional organoid model derived from
Hereditary angioedema, a C1 inhibitor deficiency that is caused by
Kidney cancer is one of the most common types of
Researchers have used CRISPR/Cas9 technology to engineer donor T cells
CAR T cells currently in clinical use are designed to
CAR T cells currently in clinical use are designed to
A team led by researchers at Massachusetts General Hospital has